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Analysis of KIT, SCF, and Initial Screening of SLUG in Patients
with Piebaldism
To the Editor:
Piebaldism is an autosomal dominantly inherited disorder
characterized by congenital leukoderma, typically on the
forehead, abdomen, and knees. The leukoderma is usually
stable throughout life, although pigmented macules may
develop at the margins and even within the white macules
(Fukai et al, 1989). KIT mutations have been demonstrated
in about 75% of patients with piebaldism (Ezoe et al, 1995).
A mouse model for human piebaldism, W dominant white
spotting, similarly results from mutations involving the
murine Kit locus. Mutations of stem cell factor in steel (sl)
mutant mice are associated with W-like abnormalities of
pigmentation (Chabot et al, 1988; Geissler et al, 1988). In
addition, deletions in the SLUG gene, which is a zinc-finger
neural crest transcription factor, have been reported re-
cently in human piebaldism that lacked mutations in KIT
(Sanchez-Martin et al, 2003).
From 1998 to 2003, we had the opportunity to examine
30 families with human piebaldism. Eight novel mutations
found were already reported elsewhere (Richards et al,
2001; Murakami et al, 2004; Shears et al, 2004). Here, we
report the result of the analysis of the remaining 22 families
with piebaldism.
Genomic DNA was prepared from peripheral blood le-
ukocytes. All 21 exons and flanking intron sequences of the
KIT gene were amplified by PCR as described (Giebel et al,
1992). PCR products were gel-purified and direct-se-
quenced using the Big Dye Terminator Cycle Sequencing
Ready Reaction Kit (Applied Biosystems, Foster City, Cal-
ifornia) and an ABI310 automated sequencer (PE Applied
Biosystems, Tokyo, Japan). This work was approved by the
ethics committee of Osaka City University Graduate School
of Medicine (#135), and was conducted according to the
Declaration of Helsinki Principles. As shown in Table I, we
found six mutations in KIT gene, which were predicted to be
pathological. Among these, five mutations were novel: 358-
delG, IVS3-2A4G, Q346X, H650L, and D792Y (Table I).
Family 1 showed 358delG frameshift mutation, which
would result in translational truncation at codon 143, within
the ligand-binding domain. Therefore, only the KIT proteins
expressed from the normal allele can work. The relatively
mild piebaldism phenotype associated with this mutation
results from haploinsufficiency (Spritz, 1994).
Family 2 had a heterozygous transition at codon 136,
which substitutes Arg for Cys (C136R). The strongly basic
charge of the arginine within the extracellular domain
appears likely to impair ligand binding. The same mutation
has been reported previously (Fleischman et al, 1996).
Family 3 had a splice site mutation in intron 3 (IVS3-
2A4G). Peptides from this abnormal allele should have
normal amino acid sequences until codon 206, approxi-
mately two-fifths of the ligand-binding domain. If new splic-
ings occur to result in in-frame deletions or insertions, the
new KIT peptides should have impaired ligand binding.
Otherwise, the new KIT peptides should be followed by
meaningless stretches of amino acids, and terminates with-
in the ligand-binding domain. Therefore, this mutation re-
sults in haploinsufficiency.
Family 4 had a nonsense mutation at codon 346 (Q346X)
that leads to truncation of the KIT receptor within the ligand-
binding domain, and also to nonsense-mediated mRNA
decay and haploinsufficiency.
Family 5 had a heterozygous missense substitution
at codon 650 (H650L) within the tyrosine kinase domain.
Recently, the crystal fine structure of the active KIT tyrosine
kinase was determined (Mol et al, 2003). It is composed of
a smaller amino-terminal N-lobe, which is comprised of
mostly b-sheets, and a larger predominantly a-helical
carboxy-terminal C-lobe. The KIT active site is located in
the interdomain cleft between the N- and C-lobes. The
N-lobe has a single a-helical structure, called helix aC,
which directly contacts the A-loop DFP motif and nucleotide
binding site and modulates kinase activity. The His650,
mutated for leucine in this family 5, is located in a strand
connecting the helix aC and the b-sheet, three amino acids
downstream of the helix aC. This histidine faces one of
the a-helical structures of the C-lobe. It is most conceivable
that the substitution of basic and hydrophilic His650 for
Leu, which is neutral and hydrophobic, distorts the confor-
mation of the active KIT protein. As the mutation at the
same codon 650 (H650P) was reported to result in a severe
phenotype because of a dominant-negative effect
(Ezoe et al, 1995), the severe phenotype in this family
5 is also likely to be caused by the dominant-negative
effect.
Family 6 had a heterozygous missense substitution at
codon 792 (D792Y) within the tyrosine kinase domain. The
Asp792 is located in the center of the interdomain cleft of
the N- and C-lobes. The substitution of neutral Leu for
acidic Asp within the cleft may have a substantial effect on
the association of the substrate peptide with the cleft. The
severe phenotype of family 6 is probably caused by the
dominant-negative effect (Spritz, 1994). In 50 unaffected
and unrelated subjects, the above six missense mutations
were not observed, and therefore are unlikely to be poly-
morphisms.Abbreviation: SCF, stem cell factor
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For KIT-mutation-negative cases, the nine exons and
flanking introns of stem cell factor (SCF) gene (Ezoe et al,
1995) were also analyzed in the same manner as KIT gene.
But, we were not able to find mutations in the SCF gene. In
mice, a mutation in SCF or steel factor causes piebald
phenotype (Chabot et al, 1988; Geissler et al, 1988). Despite
the extensive analysis by Ezoe and us, however, mutations
in the SCF gene were not identified in human piebaldism.
Mutations in SCF probably have no phenotypic effect in
humans, or could be lethal in humans.
For KIT–SCF-mutation-negative cases, we further
screened the SLUG gene. Five regions of the SLUG gene
were first screened by single strand conformation poly-
morphism, and PCR products that showed aberrant bands
were subjected to direct-sequencing. The primer pairs used
will be obtained as supplementary data on line. In this
screening system, we could not find any mutations in the
SLUG gene.
Entire or partial deletions of the KIT gene (Ezoe et al,
1995), deletions of both KITand the PDGFRA gene (Fleisch-
man et al, 1991; Spritz et al, 1992), and deletions of the
SLUG gene (Sanchez-Martin et al, 2003) have been report-
ed in human piebaldism. Southern blotting has been the
method of first choice for detecting large deletions. We have
three genes to analyze for human piebaldism, however, and
the quantity of genomic DNA from most of the patients we
have is not enough for three Southern blotting analyses.
Because real-time quantitative PCR requires only a small
amount of genomic DNA, the establishment of a method to
detect large deletion(s) of KIT, SCF, and SLUG genes is
underway.
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Table I. Analysis of KIT, SCF, and SLUG genes in human piebaldsim
Family Country Age/sex Phenotype Result of the KIT Result of the SCF Result of the SLUG
1 Japan 1 M Mild 358delG (exon3) ND ND
2 USA Child F Mild C136R (exon3) ND ND
3 Italy 38 M Moderate IVS3-2A4G ND ND
4 Italy Child M Mild Q346X (exon6) ND ND
5 France 44 M Severe H650L (exon13) ND ND
6 Italy Child F Severe D792Y (exon17) ND ND
7 the Netherlands 43 F Moderate No mutation No mutation No mutation
8 Japan 28 F Moderate No mutation No mutation No mutation
9 Japan 0 M Severe No mutation No mutation No mutation
10 England 6 F Mild No mutation No mutation No mutation
11 Japan Adult F Severe No mutation No mutation No mutation
12 USA 6 F Mild No mutation No mutation No mutation
13 Japan 37 M Mild No mutation No mutation No mutation
14 England 23 F Mild No mutation No mutation No mutation
15 Canada 7 M Unknown No mutation No mutation No mutation
16 England 39 F Moderate No mutation No mutation No mutation
17 USA 28 F Severe No mutation No mutation No mutation
18 England 16 F Unknown No mutation No mutation No mutation
19 Italy 4 F Moderate No mutation No mutation ND
20 Colombia 11 M Moderate No mutation No mutation ND
21 England 43 F Mild No mutation No mutation No mutation
22 USA 1 F Moderate No mutation ND ND
SCF, stem cell factor; M, male; F, female; ND, non-determinant.
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